Coblopasvir

{{Short description|Drug for the treatment of hepatitis C}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name = Coblopasvir

| INN =

| type =

| image = Coblopasvir.svg

| width = 300px

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category=

| routes_of_administration =

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US =

| legal_US_comment =

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status = Rx-only

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action=

| excretion =

| CAS_number = 1312608-46-0

| PubChem = 58316387

| UNII = 67XWL3R65W

| DrugBank = DB15315

| IUPHAR_ligand =

| ChemSpiderID = 75531292

| KEGG = D12247

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| IUPAC_name = Methyl N-[(2S)-1-[(2S)-2-[5-[4-[7-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate

| C = 41 | H = 50 | N = 8 | O = 8

| StdInChI = InChI=1S/C41H50N8O8/c1-22(2)32(46-40(52)54-5)38(50)48-17-7-9-30(48)36-42-19-28(44-36)25-13-11-24(12-14-25)26-15-16-27(35-34(26)56-21-57-35)29-20-43-37(45-29)31-10-8-18-49(31)39(51)33(23(3)4)47-41(53)55-6/h11-16,19-20,22-23,30-33H,7-10,17-18,21H2,1-6H3,(H,42,44)(H,43,45)(H,46,52)(H,47,53)/t30-,31-,32-,33-/m0/s1

| StdInChI_comment =

| StdInChIKey = JBYJTCVXUMWTJJ-YRCZKMHPSA-N

}}

Coblopasvir is a pharmaceutical drug for the treatment of hepatitis C.{{cite journal | vauthors = Rao H, Song G, Li G, Yang Y, Wu X, Guan Y, Mao Q, Jiang X, Wang C, Zhang Y, Jia J, Guo X, Li C, Ning J, Qin H, Pan H, Wei L | title = Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis | journal = Journal of Viral Hepatitis | volume = 27 | issue = 1 | pages = 45–51 | date = January 2020 | pmid = 31520460 | doi = 10.1111/jvh.13208 }} It is a pan-genotypic inhibitor of HCV nonstructural protein 5A.

In China, it is approved for use in combination with sofosbuvir for treating naïve or interferon‐experienced adults chronically monoinfected patients with HCV of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.{{cite journal | vauthors = Gao Y, Kong F, Li G, Li C, Zheng S, Lin J, Wen X, Hu J, Wang X, Wu X, Xing H, Jia J, Jia Z, Guan Y, Li C, Wu G, Gao Z, Mou Z, Ning Q, Mao Q, Yang Y, Ning J, Li L, Pan H, Zhou D, Ding Y, Qin H, Niu J | title = Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial | journal = Liver International | volume = 40 | issue = 11 | pages = 2685–2693 | date = November 2020 | pmid = 33047868 | pmc = 7702130 | doi = 10.1111/liv.14633 }}